Clinical Trial Update: Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating how fasting duration and temporary cessation of GLP-1 medications (liraglutide, oral semaglutide, or injected semaglutide) influence …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Rybelsus (semaglutide)
• SAXENDA (liraglutide)
• WEGOVY (Semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity | Phase 1 | Status: RECRUITING